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Open access under the ElObjectives: Infection with the human papillomavirus (HPV) is an important risk factor for development of
head and neck squamous cell carcinoma (HNSCC). Strikingly, HPV-positive HNSCCs have a more favorable
prognosis than their HPV-negative counterparts. The current study was designed to explain this favorable
prognosis of HPV-positive HNSCC.
Materials and methods: This was performed by investigating the response of four HPV-positive and
fourteen HPV-negative HNSCC cell lines to cisplatin, cetuximab and radiation.
Results: Analysis of the responses of this cell line panel indicated that HPV-positive cells are more
resistant to cisplatin treatment than the HPV-negative HNSCCs, whereas the response to radiation and
cetuximab did not differ.
Conclusions: The current study suggests that the favorable prognosis for patients with HPV-positive
HNSCC does not seem to be related to an intrinsic sensitivity of these tumor cells to chemotherapy or
radiation in vitro.
 2013 Elsevier Ltd. Open access under the Elsevier OA license. Introduction
Head and neck squamous cell carcinoma (HNSCC) arises in the
epithelial linings of the upper aerodigestive tract, and is currently
the 6th most common cancer worldwide.1 The most important risk
factors for this type of cancer are tobacco use and alcohol consump-
tion. In addition, infection with high-risk types of the human papil-
lomavirus (HPV) has been identiﬁed as a risk factor for tumors in
the oropharyngeal subsite.2 Finally, inherited genetic disorders like
Fanconi anemia (FA) are also known to genetically predispose for
HNSCC.3
The most widely used treatment for early stage HNSCC tumors
is surgery or radiotherapy.2 For the more advanced cases surgery is
combined with postoperative radiotherapy. During the past
decade, organ preservation protocols with chemoradiation are also
increasingly applied to these cases, where cisplatin-based chemo-the Centre for Translational
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sevier OA license. therapy is combined with concurrent locoregional radiotherapy.4
More recently, targeted drugs have been introduced into the
treatment protocols for HNSCC, in which cetuximab, an antibody
targeting the epidermal growth factor receptor (EGFR), is com-
bined with radiotherapy.5
Even though the general treatment protocols are being opti-
mized and intensiﬁed, the current 5-year survival rates for HNSCC
patients are around 40–50%. The prognosis for HNSCC patients is
largely determined by the tumor stage at time of presentation.2 Re-
cently it became apparent that the HPV status of the tumor also
possesses powerful prognostic value, where HPV positive patients
have a more favorable prognosis.6 This more favorable prognosis
might be attributed to intrinsic properties of HPV-positive tumor
cells, such as an increased sensitivity to the applied therapies, a
decreased proliferation rate, or an improved immune response of
the patients directed towards the virus. A comparative in vitro
study of cell lines with the intention to shed light on the better
treatment response of HPV-positive HNSCC, is still lacking.
Therefore, we studied whether the presence of HPV in a panel of
HNSCC cell lines correlates with an improved intrinsic response
to radiation, cisplatin or cetuximab. This information might be of
help to explain the favorable prognosis of HPV-positive tumors,
and might aid in the design of de-intensifying clinical trials for
HPV-positive patients.
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Cell culture
All cell lines used in this study were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM), containing 5% fetal calf serum
(FCS), 2 mM L-glutamine and antibiotics.7 Cultures were main-
tained at 37 C in a humidiﬁed atmosphere with 5% CO2. Head
and neck squamous cell carcinoma (HNSCC) cell lines UM-SCC-6,
UM-SCC-11B, UM-SCC-14C, UM-SCC-22A, UM-SCC-22B, UM-SCC-
38, UM-SCC-47 (HPV-positive) were obtained from Thomas Carey
(University of Michigan, USA).8 FaDu cells were purchased from
the ATCC, UD-SCC-2 (HPV-positive) was obtained from Christoph
Sproll (University of Düsseldorf, Germany) and UPCI-SCC90
(HPV-positive) was obtained from Susanne M. Gollin (University
of Pittsburgh, USA). Cell lines VU-SCC-1131, VU-SCC-1365, VU-
SCC-120, VU-SCC-040, VU-SCC-096, VU-SCC-147 (HPV-positive),
VU-SCC-017 and VU-SCC-OE were previously established at the
VU University Medical Center, The Netherlands.9,10 Cell lines were
authenticated by PCR proﬁling and TP53 sequencing. HPV status
was conﬁrmed by a GP5+/6+ DNA PCR.11
Determination of sensitivity to chemotherapy
Sensitivity to cisplatin (Pharmachemie B.V., Haarlem, The
Netherlands) and cetuximab (Merck, Darmstadt, Germany) wasFigure 1 Sensitivity of HNSCC cell lines to cetuximab treatment. (A) Representative do
survival for a speciﬁc cetuximab concentration, plus and minus standard deviation. Valu
the curves (RAUCs) were calculated from the cetuximab dose response curves. Bars repre
curve. Bars of the HPV-negative cell lines are shown in grey, whereas the bars of HPV-pdetermined by analysis of cell viability after treatment with a serial
dilution of these agents. The cisplatin response curves of the HPV-
negative cell lines have been published previously (Martens-de
Kemp et al, in press). In short, cells were seeded in 96-well plates
at densities that allowed exponential growth for the duration of
the experiment. Cells used for cisplatin treatment were seeded in
medium containing 5% FCS, whereas for cetuximab medium with
1% FCS was used to reduce the excess of growth factors in serum.
After 24 h, a serial dilution of either cisplatin (0–670 lM) or cetux-
imab (0–0.1 lM) was added. Cell viability was determined by a
CellTiter-Blue assay (Promega, Leiden, The Netherlands) after an-
other 72 h of growth in the presence of cisplatin, or 120 h after
cetuximab treatment. Fluorescence was analyzed using an Inﬁnite
200 microplate reader (Tecan, Giessen, The Netherlands). IC50 val-
ues were determined using GraphPad Prism software. The relative
area under the curve was calculated using Excel software.
Determination of sensitivity to radiation
Sensitivity to radiation was determined by measuring cell via-
bility after treatment with a range of 1–4 Gray (Gy) of c-radiation.
Cells were seeded in 96-well plates at optimal densities that sus-
tained exponential growth for the duration of the experiment.
After 24 h, cells were irradiated at room temperature using a
60Co source (Gammacell 220; MDS Nordion, Ontario, Canada). Cell
viability was determined after another 72 hours of growth, by ase response curves of two cell lines from the panel. Squares indicate the relative
es represent the means of three independent experiments. (B) Relative areas under
sent the mean plus standard deviation of three independent relative areas under the
ositive lines are represented in black.
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cence was analyzed using an Inﬁnite 200 microplate reader (Tecan,
Giessen, The Netherlands).
To measure clonogenic survival of 5 cell lines with different
radiosensitivities, cells were diluted to a single cell suspension
and seeded in 25 cm2 ﬂasks. Flasks were irradiated by single doses
of c-radiation in the range of 1–4 Gy. Cells were grown for a period
of 7–14 days. Subsequently, cells were ﬁxed, using 100% EtOH and
stained with Giemsa’s azur eosin methylene blue solution (Merck,
Germany). Colonies of >50 cells were counted.Cell migration assay
For the cell migration assays, cells were seeded at high density
in 12-well plates. When conﬂuency was reached, cells were cul-
tured at low serum in DMEM containing 1% FCS for 24 h. Subse-
quently, a scratch was made and cell migration was monitored
after 17 h. To quantify migration, pictures were made using a Leica
DFC320 camera (Leica, Heerbrugg, Switzerland) immediately afterFigure 2 Sensitivity of HNSCC cell lines to radiation. (A) Representative dose response
indicated radiation dose, plus and minus standard deviation. Values represent the means
calculated from the radiation dose response curves. Bars represent the mean plus stand
curve were calculated from a dose response curve made of a radiation range between 0 a
HPV-positive lines are represented in black.the generation of the scratch and at termination of the experiment.
Leica Application Suite software was used to measure the width of
the scratch.Proliferation assay
Cells were seeded in 6-well plates and left for 24 h to reach
exponential growth rates. Cell numbers were counted using a
TC10 cell counter (Biorad) on 3 subsequent days.12 The population
doubling times were calculated using Excel software.Results
A panel of 18 HNSCC cell lines was subjected to treatment with
cisplatin, cetuximab or c-irradiation in order to investigate the
relative sensitivity. The cell line panel consisted of four HPV-
positive tumor cell lines (UD-SCC-2, UM-SCC-47, UPCI-SCC090
and VU-SCC-147), two Fanconi Anemia (FA) derived HNSCC lines
(VU-SCC-1131 and VU-SCC-1365) and 12 cell lines derived fromcurves of two cell lines from the panel. Dots indicate the relative survival for the
of three independent experiments. (B) Relative areas under the curves (RAUCs) were
ard deviation of three independent relative areas under the curve. Areas under the
nd 4 Gy, with 5 different doses. HPV-negative cell lines are shown in grey, whereas
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UM-SCC-14C, UM-SCC- 22A, UM-SCC-22B, UM-SCC-38, VU-SCC-
040, VU-SCC-096, VU-SCC-120, VU-SCC-017 and VU-SCC-OE).
First, the sensitivity to the EGFR targeting monoclonal antibody
cetuximab of all 18 cell was tested. Representative dose response
curves for a relatively sensitive (VU-SCC-1365) and resistant
(UM-SCC-14C) cell line are shown in Fig. 1A. To quantify the re-
sponse to cetuximab, relative areas under the curve (RAUCs) were
calculated for all cell lines (Fig. 1B). Interestingly, the FA cell line
VU-SCC-1365 had the lowest RAUC, and is therefore the most sen-
sitive cell line tested, whereas the other FA cell line, VU-SCC-1131,
displayed the lowest sensitivity of all lines. Compared to the other
14 cell lines, the HPV-positive cell lines did not display a different
sensitivity to cetuximab, as determined with a Mann–Whitney U
test (p = 0.798).
Secondly, the sensitivity to radiotherapy of all cell lines in the
panel was tested, using a range of radiation doses between 0 and
4 Gy. The gold standard for radiosensitivity measurements is the
clonogenic assay, but several cell lines in our HNSCC panel are not
able to grow in colonies. Therefore we explored the use of a cell via-
bility assay to determine radiosensitivity. Statistical comparison of
the clonogenic assay and a cell viability assay in 5 different cell lines
revealed a high correlation between the different methods at low
radiation doses, showing the validity of the use of the cell viability
assay to determine radiosensitivity (Supplementary Fig. S1, Spear-Figure 3 Sensitivity of HNSCC cell lines to cisplatin treatment. (A) Representative dose r
cisplatin dose response curves. Bars represent the mean plus standard deviation of three i
HPV-positive lines are represented by the black bars.man correlation coefﬁcient = 0.9). Representative dose response
curves obtained by the cell viability assay of a relatively sensitive
(VU-SCC-040) and resistant (UPCI-SCC090) cell line are shown in
Fig. 2A. The relative areas under the dose response curves obtained
for all the cell lines are displayed in Fig. 2B. Both FA lines (VU-SCC-
1131 and VU-SCC-1365) are amongst the most radiosensitive lines.
This is somewhat remarkable as a defect in the FA pathways typi-
cally causes sensitivity to DNA cross-links, and not to radiation-
induced DNA damage.13 A Mann–Whitney U test showed that
the HPV-positive cell lines did not have a different sensitivity to
radiotherapy compared to the HPV-negative lines (p = 0.382).
Thirdly, the sensitivity of the cell lines to cisplatin was tested.
Representative dose response curves for two of the cell lines are
shown in Fig. 3A. To quantify the response to cisplatin, IC50 values
were calculated for all cell lines (Fig. 3B). Again the FA derived cell
lines were amongst the most sensitive lines, reﬂecting the absence
of a functional DNA damage response as expected. Strikingly, the
HPV-positive cell lines seemed to be amongst the cell lines that
are most resistant to cisplatin treatment. As this proved to be a sig-
niﬁcant difference (p = 0.008, Mann–Whitney U test), HPV presence
correlates with a relative resistance to cisplatin treatment in vitro.
Next, the migratory capacity of the cell line panel was deter-
mined. Representative pictures of a relatively slow (UM-SCC-6)
and fast (VU-SCC-1365) migrating cell line are shown in Figure
4A. Overall, the cell lines displayed a wide variety of migratoryesponse curves of two cell lines from the panel. (B) IC50-values calculated from the
ndependent IC50 measurements. HPV-negative cell lines are shown in grey, whereas
Figure 4 Migration rate of HNSCC cell lines. (A) Representative photographs of the scratch assay at t = 0 h and at the termination of the experiment (t = 17 h). (B) Bars
represent the mean migration rate plus standard deviation from three independent assays. HPV-negative cell lines are shown in grey, whereas HPV-positive lines are
represented in black.
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different rate of migration in comparison to the rest of the cell line
panel (p = 0.327, Mann-Whitney U test).
To exclude a possible effect of growth rate on the observed re-
sponses to radiation, cisplatin and cetuximab, the population dou-
bling time of all cell lines was determined (Fig. 5). A difference in
growth rate was observed between the HPV-positive cell lines
and the HPV-negative ones, with a signiﬁcantly higher population
doubling time for the HPV-positive cell lines (p = 0.025, Mann–
Whitney U test). Pearson correlation analysis showed that growth
rate itself, however, does not correlate with response to any of the
applied treatments (p > 0.05, Supplementary Table I).
Discussion
The role of HPV infection in human cancer has been a major
subject of investigation in HNSCC. Although the tumorigenic
capacity of the high risk types of this virus has clearly been shownin this tumor type, the mechanism underlying the better treatment
response in patients has not been clearly established. Studies in
cervical cancer have suggested that HPV-positive tumors possess
an intrinsic insensitivity to radio- and chemotherapy.14,15 On top
of that, inactivation of the E6 and/or E7 proteins of the virus in tu-
mor cells was shown to enhance the sensitivity to treatment,
showing the negative relation between presence of HPV and re-
sponse to treatment.16–18 These observations suggest that HPV it-
self relates to a poor response to therapy in cervical cancer. This,
however, is in sharp contrast to the notion that HPV-positive
HNSCC have a more favorable prognosis than HPV-negative
HNSCC.6 The underlying mechanism that is causative for a better
response is unknown at this point, but could possibly be attributed
to intrinsic characteristics of HPV-positive HNSCC cells. The better
response could be caused by an increased sensitivity of HPV-posi-
tive cells to the applied therapies, a slower growth rate of the cells,
an improved immune response directed towards the virus, or a
combination of these factors. More knowledge on this subject is
Figure 5 Growth rate of HNSCC cell lines. Population doubling time in hours. Bars represent the mean plus standard deviation of three independent growth curves. HPV-
negative cell lines are shown in grey, whereas HPV-positive lines are represented in black.
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treatment protocols for patients with HPV-positive tumors.
In the current study we investigated whether HPV-positive cell
lines have an improved response to therapy. Therefore the re-
sponse of a panel of 18 cell lines to common therapeutic agents
was determined. The sensitivity to radiation and cetuximab be-
tween HPV-positive and HPV-negative cell lines did not differ,
but unexpectedly, the HPV-positive cells were signiﬁcantly less
sensitive to cisplatin treatment. This seems in contrast to the stud-
ies in cervical cancer cell lines, which showed that the presence of
HPV associates with a low sensitivity to all applied therapies.14,15 It
also contrasts the study of Spanos at al., in which it was shown that
HPV-positive HNSCC cell lines are intrinsically insensitive to both
radiation and cisplatin in vitro, as compared to HPV-negative cell
lines.19 Our data, on the other hand, indicate that HPV-positive
HNSCC cells are more resistant to cisplatin treatment in vitro,
but are equally sensitive to radiation and cetuximab. These differ-
ences in observations might be caused by the use of a larger cell
line panel in the current study. The ﬁnding that HPV-positive cells
are relatively unresponsive to cisplatin provides a rationale to eval-
uate the added value of cisplatin in the treatment protocols for
HPV-positive HNSCCs in prospective clinical trials. Nevertheless,
the data on sensitivity of the cell line panel used in this study
should be taken with caution, as it might not fully represent the ac-
tual sensitivity of the tumors.
Even though we provide some evidence that HPV-positive cells
do not possess an enhanced sensitivity to cisplatin, cetuximab and
radiation in vitro, this is not easily translated to the in vivo situa-
tion. The use of a cell line panel to evaluate sensitivity to clinicallyapplied agents has limitations. The availability of only 4 HPV-posi-
tive cell lines, which are difﬁcult to establish, might not be sufﬁ-
cient to fully reﬂect the wide variety of tumors in patients.
Moreover, cell lines in tissue culture are known to behave differ-
ently when compared to tumors xenografted in mice or as they
present in patients. Furthermore, it has been suggested that im-
mune clearance is an important determinant for treatment re-
sponse of HPV-positive tumors.19,20 This indicates that host
factors might be an important determinant for the response to
the applied therapy. Against this likely hypothesis is the clinical
observation that HPV-positive tumors are generally of less ad-
vanced T-stage but higher N stage. Hence, these tumors easily form
metastases in the lymph nodes, suggesting a strong immune sup-
pressive activity. Whether the application of chemoradiation
in vivo could trigger an enhanced immunological response to the
HPV virus by the induction of tumor cell kill, remains to be
determined.
HPV-positive tumors are characterized by a higher nodal metas-
tasis and lower T-stage at time of presentation, suggesting a rela-
tively low proliferation rate and an enhanced metastatic
capacity.21 Our data indeed show a signiﬁcantly lower growth rate
for HPV-positive cells when compared to HPV-negative cells,
which might relate to the smaller T-stages observed for HPV-posi-
tive HNSCC. The absence of a correlation between growth rate and
response to any of the therapeutic agents used in this study sug-
gest that this growth rate is not the main determinant for the ob-
served response.
In summary, we provide evidence that HPV-positive HNSCC
cells proliferate slower and are intrinsically less sensitive to cis-
566 R. Nagel et al. / Oral Oncology 49 (2013) 560–566platin treatment in vitro than HPV-negative cells. Their response to
radiation and cetuximab are not different, and also the migratory
capacity seems comparable. These data suggest that the better
treatment response of HPV-positive tumors is not easily explained
by an intrinsic sensitivity to chemoradiation. With the more favor-
able prognosis of HPV-positive HNSCC in mind, it has been sug-
gested that this subgroup of patients may beneﬁt from de-
intensiﬁed treatment protocols, which should be studied in clinical
trials.22 Altogether the in vitro data presented here do suggest that
a critical evaluation of the added value of cisplatin in comparison
to other agents in the treatment of HPV-positive HNSCC might be
valuable.Conﬂict of interest statement
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